JOHN L LAMATTINA
CIK 1216074 · Senior Vice President · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$19.66M
Companies
6
Total Filings
90
Lifetime Open-Market Net
-$7.28M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LGND | Director | 26,969 | $300.79 | $8.11M | -$6.11M | 32 | 2026-06-12 |
| IMNM | Director | 66,953 | $25.06 | $1.68M | $101.0K | 7 | 2023-06-12 |
| Larimar Therapeutics, Inc. (ZFGN) Delisted | Director | 2,615 | — | — | $0 | 10 | 2019-06-27 |
| HUMAN GENOME SCIENCES INC (HGSI) Delisted | Director | 42,843 | — | — | $51.0K | 9 | 2012-08-01 |
| NEUROGEN CORP (NRGN) Delisted | Director | — | — | — | $0 | 9 | 2009-12-17 |
| PFE | Senior Vice President | 388,288 | $25.41 | $9.87M | -$1.32M | 19 | 2007-10-17 |
Recent Filings · Page 5 of 9
90 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-01-27 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-11-13 | LGND | Gift (G) | −1,500 | $0 | EDGAR |
| 2015-07-15 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-04-27 | LGND | Grant (A) | +925 | $0 | EDGAR |
| 2015-01-12 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-11-26 | LGND | Gift (G) | −2,785 | $0 | EDGAR |
| 2014-03-20 | LGND | Mixed | — | -$349.3K | EDGAR |
| 2013-11-21 | LGND | Gift (G) | −3,800 | $0 | EDGAR |
| 2013-06-12 | LGND | Grant (A) | +3,621 | $0 | EDGAR |
| 2012-08-01 | HUMAN GENOME SCIENCES INC (HGSI) Delisted | Mixed | −47,009 | -$669.9K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.